Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV).

Topics covered:

Why fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to change

The diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementation

The recent FDA approval of bulevirtide (Livdelzi) for chronic HDV infection, including dosing, administration, and the combination vs. monotherapy question

10 mg vs. 2 mg dose considerations and off-treatment response data

Phase 3 pipeline

For more: https://www.hcplive.com/view/liver-lineup-hdv-diagnosis-bulevirtide-and-the-delta-pipeline